Thymalin

Identity unlike the synthetic single peptides elsewhere in this register, Thymalin is a polypeptide complex extracted from the thymus of young calves (by mild acid extraction) and standardized as a pharmaceutical. The thymus is the organ that "educates" T-lymphocytes; Thymalin is positioned as a thymic immune-restorative / immunocorrector. It's the prototype of the "peptide bioregulator" concept — the idea that short peptides act as precise regulators of gene expression in specific tissues rather than as blunt pharmacological agents. ## Mechanism (as proposed) Thymalin's activity is attributed to its short peptides — KE (Lys-Glu), EW (Glu-Trp), EDP (Glu-Asp-Pro) — which are proposed to bind directly to double-stranded DNA and/or histone proteins and thereby regulate gene expression: the synthesis of immune-system proteins, cytokines, heat-shock proteins, "gerontogenes," and the differentiation/proliferation of stem and immune cells (while reducing apoptosis). Functionally, the pitch is restoring the aging thymus's T-cell output and thus pushing back on immunosenescence — and, in the geroprotection framing, "normalizing" cardiovascular/endocrine/immune/nervous-system indices. This "short peptides as epigenetic gene-expression regulators" model is the theoretical heart of the entire bioregulator school. It is mechanistically coherent and supported by the group's own molecular work, but — like the clinical claims — not broadly validated by independent labs.